{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-316916","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-07-27T12:00:16+00:00","discovered_at":"2026-07-27T12:05:00.396228+00:00","generated_at":"2026-07-27T12:05:38.027138+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kyverna signs commercial manufacturing deal with ElevateBio for miv-cel; BLA on track for Q4 2026","bullets":["Agreement covers U.S. commercial and global clinical supply of miv-cel, replacing prior clinical deal.","Supports potential launches in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG).","Rolling BLA submission for miv-cel in SPS remains on track for Q4 2026.","ElevateBio achieved >98% clinical manufacturing success rate for miv-cel.","Initial five-year term with automatic renewals; minimum purchase commitments and annual PPI-based price adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-316916","json":"https://secwatch.observer/filing/0001193125-26-316916.json","markdown":"https://secwatch.observer/filing/0001193125-26-316916.md","text":"https://secwatch.observer/filing/0001193125-26-316916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526316916/0001193125-26-316916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526316916/kytx-20260723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T12:05:38.027138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}